Skip to main content

Table 1 Patient characteristics ( n = 79)

From: Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock

  S group (n= 42)a H group (n= 37)a P value
Age (years) 66.7 ± 2.0 67.7 ± 2.2 0.744
Gender (male/female) 21/21 25/12 0.057
Body height (cm) 159.9 ± 1.4 161.4 ± 1.6 0.465
Body weight (kg) 54.6 ± 2.0 53.5 ± 2.0 0.699
APACHE II score 25.5 (13–39) 27 (8–43) 0.115
APACHE II(−GCS) 17 (8–29) 17 (8–32) 0.936
SOFA score 11 (3–15) 10 (4–17) 0.462
SOFA(−GCS) 8 (2–14) 6 (1–13) 0.117
Clinical stratification (sever sepsis/septic shock) 4/38 5/32 0.418
Source of infection    
 Generalized peritonitis 15 (35.7%) 13 (35.1%)  
 Pneumonia 4 (9.5%) 6 (16.2%)  
 Urinary tract 6 (14.3%) 2 (5.4%)  
 Bacteremia 4 (9.5%) 3 (8.1%)  
 Cellulitis 2 (4.8%) 2 (5.4%)  
 Biliary tract 2 (4.8%) 1 (2.7%)  
 Others 5 (11.9%) 6 (16.2%)  
 Unknown 4 (9.5%) 4 (10.8%)  
  1. aPatients in the S group were administered a standard IVIG dose of 5 g/day for 3 days; patients in the H group were administered a single high dose of 15 g/day for 1 day. Continuous variables: mean ± SEM; ordinal variables: median (interquartile); nominal variables: percentage. APACHE II, Acute Physiology and Chronic Health Evaluation II; APACHE II(−GCS), APACHE II without Glasgow Coma Scale; SOFA, Sequential Organ Failure Assessment; SOFA(−GCS), SOFA without Glasgow Coma Scale.